Fisher & Paykel Healthcare's EBIT per Share for the
six
months ended in Mar. 2026 was A$0.50.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.93.
During the past 3 years, the average EBIT per Share Growth Rate was 25.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Fisher & Paykel Healthcare's EBIT per Share or its related term are showing as below:
ASX:FPH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.7 Med: 8.55 Max: 77.6
Current: 25
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Fisher & Paykel Healthcare was 77.60% per year. The lowest was -45.70% per year. And the median was 8.55% per year.
ASX:FPH's 3-Year EBIT Growth Rate is ranked better than 70.43% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs ASX:FPH: 25.00
Fisher & Paykel Healthcare (ASX:FPH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Fisher & Paykel Healthcare EBIT per Share Related Terms
Fisher & Paykel Healthcare EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a EBIT per Share of A$0.93 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fisher & Paykel Healthcare and its competitors. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #204 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 29.6%.
Is Fisher & Paykel Healthcare's EBIT per Share too high?
Fisher & Paykel Healthcare's current EBIT per Share is A$0.93. Based on the distribution chart, Fisher & Paykel Healthcare ranks #204 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #204 out of 690 companies for EBIT per Share. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EBIT per Share is A$0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.35, compared to a current price of A$31.81 — trading 12.5% below its estimated fair value. The current EBIT per Share is A$0.93. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current EBIT per Share is A$0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$31.81 is trading 12.5% below its estimated GF Value™ of A$36.35.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
EBIT per Share: A$0.93
GF Value™: A$36.35 vs. price of A$31.81 (12.5% below fair value)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
